Expression Of CD133and MEK1/2and Their Correlation In Stage Ⅱ Colorectal Cancer

Background and ObjectiveColorectal cancer is one of the most common gastrointestinal cancer, with high mortality and poor prognosis, malignant transforms from colorectal epithelial, the development is a complexity accumulation process involving multiple genes. Early detection, early diagnosis, and early treatment are the keys to improve the therapeutic effect of colorectal cancer. Whether an adjuvant therapy is needed for a postoperative patient with stage II colorectal cancer has been controversial for a long time. Thanks to the development of science and technology, the diagnosis and treatment of tumor no longer stays in location and morphology, but with the combination of morphology and function change, gradually turn to a further diagnosis and treatment development as cytology, molecular biology, and genomics. Recent studies have found that CD133is the best cancer stem cell of colorectal tumor, and the abnormal expression of MEK1/2associated with the development of colorectal cancer, both are expected to be the effective therapy targets in the future. In this research, we analysis the expression and correlation of CD133and MEK1/2in stage Ⅱ colorectal cancer, studied their relationship with stage Ⅱ colorectal cancer and the clinical significance, in order to provide a theoretical basis for the establishment of postoperative treatment strategy for patients with stage Ⅱ colorectal cancer.MethodsThe clinicopathologic data of patients with stage Ⅱ colorectal cancer was collected.Slice the paraffin-embedded specimen postoperative.The expression of CD133and MEK1/2in cancer tissue and adjacent tissues was detected with SP immunohistochemisty (IHC).Analysis the correlation between the expression of CD133and MEK1/2with clinical features (including gender, age, the location of tumor), pathological pattern, differentiation, high risk factors, invasion depth serum tumor markers (CEA, CA199) together with the MSI status.ResultsNo significant correlation was found between the MSI status with the clinical features (including gender, age, the location of tumor), pathological pattern, differentiation, high risk factors, invasion depth and serum tumor markers (CEA, CA199)(P>0.05).CD133and MEK1/2expression in the cancer tissue and adjacent tissues have obvious difference (P<0.01).95cancer tissues in total, CD133high express in74cases, MEK1/2high express in75cases, and for the adjacent tissue, only19cases express high. At the same time, the study show that CD133、MEK1/2high expression has no significant correlation with the clinical features (including gender, age, the location of tumor), pathological pattern, high risk factors, invasion depth and serum tumor markers (CEA, CA199)(P>0.05),but has negative correlation with tumor differentiation (P<0.01),poor differentiated cases express high.Comprehensive analysis, we found that CD133has correlation with MEK1/2,70cases MEK1/2express high in the CD133high express cases,4cases express low, while,5cases MEK1/2express high in the CD133low express cases,16cases express high. Spearman correlation analysis showed that the two were positively correlated (P<0.001) Conclusions1. The expression of CD133and MEK1/2are positively correlated, both of them are significantly increased in tumor tissues of patients with stage Ⅱ colorectal cancer.They have negative correlation with differentiation, poor differentiation with high expression. No obvious correlation was found with clinical characteristics.2. The expression of CD133and MEK1/2has no obvious correlation with the MSI status.3. The MSI status has no obvious correlation with clinical features in patients with stage Ⅱ colorectal cancer.